WallStreetZenWallStreetZen

NASDAQ: MESO
Mesoblast Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for MESO

Based on 3 analysts offering 12 month price targets for Mesoblast Ltd.
Min Forecast
$1.50+22.95%
Avg Forecast
$6.83+460.08%
Max Forecast
$17.00+1,293.44%

Should I buy or sell MESO stock?

Based on 3 analysts offering ratings for Mesoblast Ltd.
Hold
Strong Buy
1 analysts 33.33%
Buy
0 analysts 0%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
1 analysts 33.33%

Be the first to know when Wall Street analysts revise their MESO stock forecasts and price targets.

MESO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Cantor Fitzgerald
Bottom 2%
2
Strong BuyReiterates$17.00+1,270.97%2023-09-21
Piper Sandler
Bottom 3%
3
HoldDowngrades$2.00+61.29%2023-08-04
Chardan Capital
Top 9%
92
Strong SellMaintains$1.50+20.97%2023-08-04

1 of 1

Forecast return on equity

Is MESO forecast to generate an efficient return?
Company
1,110.56%
Industry
0.91%
Market
28.82%
MESO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MESO forecast to generate an efficient return on assets?
Company
832.55%
Industry
0.07%
MESO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MESO revenue growth forecast

How is MESO forecast to perform vs Biotechnology companies and vs the US market?
Company
436.04%
Industry
35.95%
Market
8.15%
MESO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MESO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MESO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MESO$1.24$6.83+451.05%Hold
CRMD$3.67$12.33+236.05%Buy
VIGL$5.59$18.75+235.42%Buy
STRO$3.30$17.50+430.30%Strong Buy
FENC$7.49$16.50+120.29%Strong Buy
View Top Biotech Stocks

Mesoblast Stock Forecast FAQ

Is Mesoblast Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: MESO) stock is to Hold MESO stock.

Out of 3 analysts, 1 (33.33%) are recommending MESO as a Strong Buy, 0 (0%) are recommending MESO as a Buy, 1 (33.33%) are recommending MESO as a Hold, 0 (0%) are recommending MESO as a Sell, and 1 (33.33%) are recommending MESO as a Strong Sell.

If you're new to stock investing, here's how to buy Mesoblast stock.

What is MESO's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: MESO) forecast ROE is 1,110.56%, which is considered strong.

What is MESO's Price Target?

According to 3 Wall Street analysts that have issued a 1 year MESO price target, the average MESO price target is $6.83, with the highest MESO stock price forecast at $17.00 and the lowest MESO stock price forecast at $1.50.

On average, Wall Street analysts predict that Mesoblast's share price could reach $6.83 by Sep 21, 2024. The average Mesoblast stock price prediction forecasts a potential upside of 451.05% from the current MESO share price of $1.24.

What is MESO's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: MESO) forecast ROA is 832.55%, which is higher than the forecast US Biotechnology industry average of 0.07%.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.